Please assess the completion status of the following clinical trial:

Trial Title: Clinical Trial of Temisartan/Amlodipine & Rosuvastatin in Subjects With Hypertension and Hyperlipidemia

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: DOUBLE
- Phase: PHASE3
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~1. Signed informed consent~2. Subjects with hypertension and hyperlipidemia~Exclusion Criteria:~1. Patients with known or suspected secondary hypertension~2. Other exclusions applied

- Gender: ALL
- Minimum Age: 19 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Combination drug:Temisartan+Amlodipine+Rosuvastatin (Type: EXPERIMENTAL): 60 subjects will be assigned and the subjects will be administered Temisartan+Amlodipine+Rosuvastatin for 8 weeks.
- Temisartan+Amlodipine (Type: ACTIVE_COMPARATOR): 60 subjects will be assigned and the subjects will be administered Twynsta Tab.(Temisartan+Amlodipine) for 8 weeks.
- Temisartan+Rosuvastatin (Type: ACTIVE_COMPARATOR): 60 subjects will be assigned and the subjects will be administered Micardis Tab. and Crestor Tab.(Temisartan+Rosuvastatin) for 8 weeks.

Based on this trial design, predict the completion outcome and termination type (if applicable).